Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06238297 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Rapid De-escalation of Anti-MRSA Therapy Guided by S. Aureus Nares Screening in Case of Pneumonia

Study acronym: SNAP
StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated May 30, 2025 (before its estimated June 3, 2025 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial status: Not Yet Recruiting to Recruiting
    • Primary completion date: Feb 10, 2025 to Jun 3, 2025
    • Study completion date: Feb 10, 2025 to Jun 30, 2025
    • Start date changed from estimate of Feb 10, 2024 to May 6, 2024
    v5
  2. Primary endpoints: 2 to 1
    • Secondary endpoints: 4 to 5
    v4
  3. Study description shortened, about 579 wordsv3
  4. Secondary endpoints revised (4)
    • Study description shortened, about 238 words
    • Publications: 1 to 7
    v2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The current IDSA/ATS guidelines recommend Linezolid and Vancomycin for MRSA coverage in hospitalized patients with pneumonia, which is common clinical practice in Italy. However, a nasal PCR-assay for MRSA has a high negative predictive value and can facilitate rapid antibiotic de-escalation, thereby avoiding unnecessary anti-MRSA treatments. The indiscriminate use of these drugs has contributed to the emergence of resistant S. aureus strains and has led to significant adverse effects, without providing any survival benefits. Additionally, it has increased hospital stays and associated costs. The proposed study aims to use this diagnostic tool to shorten empirical anti-MRSA treatment duration in pneumonia patients, focusing on reducing antimicrobial therapy days while measuring in-hospital mortality, length of stay and adverse drug event incidence.
Trial Details
NCT Number NCT06238297
Lead Sponsor University of Bari Aldo Moro
Conditions
(from sponsor)		 Pneumonia, Bacterial
Related terms Pneumonia, Pneumonia, Bacterial
Enrollment 76 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov